• Richard Fisher, Jonathan Clarke, Khaled Al-Arfi, Rohit Saha, Eirini Lioudaki, Reena Mehta, Clemens Pahl, Claire Sharpe, Kate Bramham, and Sam Hutchings.
• Department of Critical Care, King's College Hospital NHS Foundation Trust, London, United Kingdom. Electronic address: richard.fisher8@nhs.net.
• J Crit Care. 2021 Apr 1; 62: 190196190-196.

PurposeThe aim of this study is to describe the incidence of Acute Kidney Injury (AKI) amongst patients admitted to the Intensive Care Unit (ICU) with COVID-19. In addition we aim to detail the range of Renal Replacement Therapy (RRT) modalities offered to these patients (including peritoneal dialysis - PD - and intermittent haemodialysis - IHD) in order to meet demand during pandemic conditions.Materials And MethodsSingle-centre retrospective case note review of adult patients with confirmed COVID-19 admitted to ICU.ResultsAmongst 136 patients without a prior history of End Stage Kidney Disease (ESKD), 108 (79%) developed AKI and 63% of admitted patients received RRT. Due to resource limitations the range of RRT options were expanded from solely Continuous Veno-Venous HaemoDiaFiltration (CVVHDF - our usual standard of care) to include PD (in 35 patients) and IHD (in 15 patients). During the study period the proportion of RRT provided within ICU as CVVHDF fell from 100% to a nadir of 39%. There were no significant complications of either PD or IHD.ConclusionsDuring periods of resource limitations PD and IHD can safely be used to reduce dependence on CVVHDF in select patients with AKI secondary to COVID-19.Copyright © 2021. Published by Elsevier Inc.

29 keywords...

hide…